Skip to main content
DRUG
NASDAQ Life Sciences

FDA Partial Hold Halts U.S. Phase 2 Pediatric Epilepsy Trial; Shares Plunge 55%

Tom Rudovsky · Reported by Benzinga
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
9
Price
$20.34
Mkt Cap
$542.326M
52W Low
$18.9
52W High
$123.75
52W Position info
7.6% above low
Off High info
84% below high
Rel. Volume info
4.1× avg
Market data snapshot near publication time

DRUG is trading near its 52-week low of $18.9 (7.6% above the low) on elevated volume (4.1× avg).

Summary

The FDA placed a partial clinical hold on Bright Minds' IND and protocol for developmental and epileptic encephalopathies, blocking the planned U.S. Phase 2 trial of BMB-101 while other studies continue. Regulators cited toxicity seen in mice plus inadequate pharmacokinetic and juvenile toxicity data to support pediatric enrollment. The company argues the mouse finding was incidental rather than drug-related, but concedes those are its own interpretations, not FDA conclusions. Shares fell 55% to $24.72 on the news. The formal Partial Clinical Hold Letter is due within 30 days and will spell out the trial-design fixes required; management warned future U.S. trials may need additional data or studies and gave no assurance the hold gets lifted.

Updates

  1. · SEC 6-K — Bright Minds said the FDA's partial clinical hold email cited mouse toxicity and inadequate pharmacokinetic and juvenile toxicity data, and that the full hold letter is due within 30 days.

At the time of this announcement, DRUG was trading at $20.34 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $542.3M. The 52-week trading range was $18.90 to $123.75. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: Benzinga.


Price Chart

Share this article

Copied!

DRUG - Latest Insights

DRUG
Nov 02, 2026, 4:30 PM EST
Filing Type: 6-K
Importance Score:
9
Price at Filing: $24.54
Real-time Price: $20.88 info
Change: -$3.66 (-15%) info
Market Cap: $204.778M info
DRUG
May 19, 2026, 6:15 PM EDT
Filing Type: 6-K
Importance Score:
9
Price at Filing: $74.54
Real-time Price: $20.88 info
Change: -$53.66 (-72%) info
Market Cap: $204.778M info
DRUG
Jan 09, 2026, 4:11 PM EST
Filing Type: 6-K
Importance Score:
8
Price at Filing: $86.75
Real-time Price: $20.88 info
Change: -$65.87 (-76%) info
Market Cap: $204.778M info
DRUG
Jan 08, 2026, 7:32 PM EST
Filing Type: 6-K
Importance Score:
8
Price at Filing: $90.01
Real-time Price: $20.88 info
Change: -$69.13 (-77%) info
Market Cap: $204.778M info
DRUG
Jan 08, 2026, 7:02 PM EST
Filing Type: 424B5
Importance Score:
8
Price at Filing: $90.01
Real-time Price: $20.88 info
Change: -$69.13 (-77%) info
Market Cap: $204.778M info